Valeant Pharmaceuticals (VRX) is down on Teva's woes.But debt reduction, cash flow growth, non-GAAP growth and B+L sales increases will lift the stock price.VRX STOCK: $BHC, Bausch Health Companies Inc. / H1 TEVA STOCK: $TEVA, Teva Pharmaceutical Industries Limited / H1 VRX 2018 PT $15.Valeant will go up after earnings on November 7 bmo. Agree or disagree?Vote with your peers - 800 members in the Value Stock Group.Agree: VRX Up after ER.Disagree: VRX will fall after earnings.